Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEX, Rituximab, and Steroids for Acute IPF Exacerbations
NCT01266317Phase 2Completed
- Start
- Mar 2011
- Primary completion
- Jul 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in idiopathic pulmonary fibrosis (IPF). Primary endpoint: Number of Participants With Respiratory and/or Hemodynamic Deteriorations at 28 days. Started Mar 2011; status: completed.
02
Drugs
rituximab
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT01266317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01266317.